Establishment Labs (NASDAQ:ESTA) Trading 3.8% Higher

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTAGet Rating) traded up 3.8% during trading on Wednesday . The stock traded as high as $61.04 and last traded at $61.04. 496 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 119,093 shares. The stock had previously closed at $58.79.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ESTA. The Goldman Sachs Group lifted their price objective on shares of Establishment Labs from $57.00 to $65.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 9th. B. Riley began coverage on shares of Establishment Labs in a research report on Tuesday, August 23rd. They set a “buy” rating and a $107.00 price objective for the company. Finally, BTIG Research decreased their price objective on shares of Establishment Labs from $105.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, June 24th.

Establishment Labs Trading Down 4.6 %

The company has a debt-to-equity ratio of 9.17, a current ratio of 4.50 and a quick ratio of 3.74. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -18.74 and a beta of 1.08. The business’s 50 day simple moving average is $61.67 and its 200 day simple moving average is $62.04.

Establishment Labs (NASDAQ:ESTAGet Rating) last posted its quarterly earnings data on Monday, August 8th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.48). The business had revenue of $41.19 million during the quarter, compared to analyst estimates of $37.80 million. Establishment Labs had a negative net margin of 49.94% and a negative return on equity of 129.28%. Research analysts anticipate that Establishment Labs Holdings Inc. will post -2.06 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Arbitrage SA increased its stake in shares of Establishment Labs by 3,244.4% during the first quarter. BNP Paribas Arbitrage SA now owns 602 shares of the company’s stock worth $41,000 after acquiring an additional 584 shares during the period. Lazard Asset Management LLC increased its stake in shares of Establishment Labs by 104.5% during the first quarter. Lazard Asset Management LLC now owns 963 shares of the company’s stock worth $64,000 after acquiring an additional 492 shares during the period. Bank of America Corp DE increased its stake in shares of Establishment Labs by 38.4% during the first quarter. Bank of America Corp DE now owns 2,227 shares of the company’s stock worth $150,000 after acquiring an additional 618 shares during the period. Ensign Peak Advisors Inc acquired a new position in shares of Establishment Labs during the fourth quarter worth about $191,000. Finally, SG Americas Securities LLC acquired a new position in shares of Establishment Labs during the first quarter worth about $202,000. 75.89% of the stock is currently owned by institutional investors and hedge funds.

Establishment Labs Company Profile

(Get Rating)

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.

Featured Articles

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.